DMAA Enters LOI for $1.0B De-SPAC with Power Analytics Global Corp.
Summary
Drugs Made In America Acquisition Corp. has signed a non-binding Letter of Intent to merge with Power Analytics Global Corp. in a de-SPAC transaction, valuing the target at approximately $1.0 billion.
Key Events
-
LOI Signed for De-SPAC Transaction
Drugs Made In America Acquisition Corp. entered into a non-binding Letter of Intent with Power Analytics Global Corp. for a de-SPAC business combination.
-
Target Valuation Set at $1.0 Billion
The proposed transaction anticipates an implied equity valuation of approximately $1.0 billion for Power Analytics Global Corp., subject to adjustments.
-
Minimum Cash Condition Expected
The definitive business combination agreement is expected to include a minimum cash condition in the range of $25 million to $50 million.
-
Potential for Additional Financing
The parties may pursue additional financing, including PIPE investments, to support the transaction.
Analysis
Drugs Made In America Acquisition Corp. (DMAA) has taken a significant step towards completing its business combination by entering into a Letter of Intent (LOI) for a de-SPAC transaction with Power Analytics Global Corp. This LOI, which anticipates valuing the target at approximately $1.0 billion, is a crucial development for the SPAC, fulfilling its primary mandate. This follows recent efforts by DMAA to secure financing and extend its deadline to complete a business combination, indicating progress towards a definitive agreement. While the LOI is non-binding and subject to further negotiation and due diligence, it signals a clear path forward for the company, especially as its stock trades near its 52-week high.
At the time of this filing, DMAA was trading at $10.51 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $352.3M. The 52-week trading range was $9.96 to $10.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.